Newcastle Disease Virus (PDQ®): Complementary and alternative medicine - Health Professional Information [NCI] - Human / Clinical Studies
Table 3. Studies of NDV-Infected Tumor Cell Vaccines in Which Therapeutic Benefit Was Assesseda
Type of Study
Type of Cancer
No. of Patients: Enrolled; Treated; Controlb
Strongest Benefit Reportedc
Level of Evidence Scoree
No. = number; wk = week.
a See text and theNCI Dictionary of Cancer Termsfor additional information and definition of terms.
b Number of patients treated plus number of patients control may not equal number of patients enrolled; number of patients enrolled = number of patients initially recruited/considered by the researchers who conducted a study; number of patients treated = number of enrolled patients who were given the treatment being studiedAND for whom results were reported; historical control subjects are not included in number of patients enrolled.
c The strongest evidence reported that the treatment under study has anticancer activity or otherwise improves the well-being of cancer patients.
d Chemotherapy, radiation therapy, hormonal therapy, or cytokine therapy given/allowed at the same time as vaccine therapy.
e For information about levels of evidence analysis and an explanation of the level of evidence scores, seeLevels of Evidence for Human Studies of Cancer Complementary and Alternative Medicine.
f Only 48 patients were treated with NDV-infected tumor cell vaccines; the remaining patients were treated with another type of vaccine.
g The patients were divided into groups that received a high-quality vaccine or a low-quality vaccine; the low-quality vaccine groups served as the controls; 32, 13, and 18 patients with early breast cancer, metastatic breast cancer, and metastatic ovarian cancer, respectively, received high-quality vaccines; the corresponding low-quality vaccine groups contained 31,14, and 13 patients.
h There were 39 evaluable patients in this study, but findings were reported for only 24 patients.
35; 23; 87 (concurrent controls identified from within same hospital)
Median progression-free survival of vaccinated patients was 40 wk (vs. 26 wk in controls; log-rank test,P = .024), median OS of vaccinated patients was 100 wk (vs. 49 wk in controls; log-rank test,P< .001)
Protocol therapy after surgical debulking of tumor followed by radiation therapy